IWC
HRTX icon

Integrated Wealth Concepts’s Heron Therapeutics HRTX Stock Holding History

Integrated Wealth Concepts’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.3K Buy
159,997
+64,499
+68% +$51.7K ﹤0.01% 2345
2026
Q1 		$76.4K Buy
95,498
+324
+0.3% +$375 ﹤0.01% 2197
2025
Q4 		$124K Sell
95,174
-2,421
-2% -$2.99K ﹤0.01% 1555
2025
Q3 		$123K Buy
97,595
+3,190
+3% +$5.06K ﹤0.01% 1904
2025
Q2 		$195K Buy
94,405
+100
+0.1% +$204 ﹤0.01% 1776
2025
Q1 		$207K Sell
94,305
-16,778
-15% -$32.6K ﹤0.01% 1603
2024
Q4 		$170K Buy
111,083
+62,305
+128% +$101K ﹤0.01% 1628
2024
Q3 		$97.1K Sell
48,778
-2,000
-4% -$4.78K ﹤0.01% 1611
2024
Q2 		$178K Buy
50,778
+2,000
+4% +$6.14K ﹤0.01% 1539
2024
Q1 		$135K Buy
48,778
+16,778
+52% +$42.2K ﹤0.01% 1563
2023
Q4 		$54.4K Buy
+32,000
New +$35.2K ﹤0.01% 1556

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Integrated Wealth Concepts's HRTX Position: Q2 2026 in Review

Integrated Wealth Concepts increased its Heron Therapeutics (HRTX) stake by 68% in Q2 2026, buying an estimated $51.7K and bringing the position to 159,997 shares worth $68.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2345.

Integrated Wealth Concepts first reported a position in HRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $207K in Q1 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Integrated Wealth Concepts held 159,997 shares of Heron Therapeutics worth $68.3K as of Q2 2026.
  • Integrated Wealth Concepts bought 64,499 Heron Therapeutics shares in Q2 2026, an estimated $51.7K.
  • Heron Therapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #2345 holding.
  • Integrated Wealth Concepts first reported a position in Heron Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Integrated Wealth Concepts's Heron Therapeutics position peaked at $207K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.